PMID- 24131018
OWN - NLM
STAT- MEDLINE
DCOM- 20140620
LR  - 20131017
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 82
IP  - 5
DP  - 2013 Nov
TI  - Association of HLA-G promoter and 14-bp insertion-deletion variants with acute 
      allograft rejection and end-stage renal disease.
PG  - 317-26
LID - 10.1111/tan.12210 [doi]
AB  - The aim of this study was to investigate the HLA-G 14-bp insertion/deletion (I/D) 
      polymorphism among end-stage renal disease (ESRD) patients. Cytomegalovirus (CMV) 
      infection, acute allograft rejection (AR) and overall survival after renal 
      transplantation was investigated in 300 ESRD patients and 302 age, sex and 
      ethnicity-matched controls. Sequencing was performed to evaluate the impact of 
      HLA-G promoter region single-nucleotide polymorphisms (SNPs) whereas 
      semi-quantitative PCR method was used to determine the probable HLA-G expression 
      pattern among ESRD and AR cases. Further, soluble human leukocyte antigen (HLA)-G 
      (sHLA-G) expression levels were compared in AR vs non-AR cases in the light of 
      HLA-G 14-bp I/D polymorphism. Increased risk was found for 14-bp D/D 
      (deletion-DD) genotype and 14-bp D allele [DD: odds ratio (OR) = 1.46, 95% 
      confidence interval (CI) = 1.03-2.06, P value = 0.0358; D: OR = 1.29, 95% 
      CI = 1.03-1.62, P value = 0.0277], respectively for ESRD and CMV infection (DD: 
      OR = 2.70, 95% CI = 1.45-5.05, P value = 0.0021; D: OR = 1.94, 95% 
      CI = 1.22-3.08, P value = 0.0052). Nearly fourfold (OR = 3.62, 95%CI = 1.61-8.14, 
      p = 0.0039) risk was observed for 14-bp I/I (insertion-II) genotype for AR. 
      Survival analysis showed increased overall survival (OS) (AR or death) for 14-bp 
      D/D genotype. HLA-G promoter region sequencing was carried out among 60 ESRD 
      patients and 100 normal controls which showed increased risk for -964 G>A, -725 
      C>G/T and -486 A>C SNPs. -964 G>A and -725 C>G/T SNPs showed risk association for 
      AR patients. High level of HLA-G transcripts was observed among non-AR patients. 
      Further soluble HLA-G (sHLA-G) showed increased levels in ESRD patients 
      (mean +/- SEM; 62.16 +/- 2.43 U/ml) as compared to controls (mean +/- SEM; 
      21.06 +/- 3.89 U/ml) (P = <0.0001). The 14-bp I/I, 14-bp I/D and 14-bp D/D 
      genotypes showed significantly higher levels of sHLA-G among non-AR as compared 
      to AR patients.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Misra, M K
AU  - Misra MK
AD  - Department of Medical genetics, Sanjay Gandhi Post-graduate Institute of Medical 
      Sciences, Lucknow, India; Department of Anatomy, Institute of Medical Sciences, 
      Banaras Hindu University, Varanasi, India.
FAU - Prakash, S
AU  - Prakash S
FAU - Kapoor, R
AU  - Kapoor R
FAU - Pandey, S K
AU  - Pandey SK
FAU - Sharma, R K
AU  - Sharma RK
FAU - Agrawal, S
AU  - Agrawal S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - Allografts/*metabolism
MH  - Base Pairing/genetics
MH  - Cytomegalovirus Infections/complications/genetics
MH  - Demography
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Frequency
MH  - *Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Graft Rejection/complications/*genetics
MH  - HLA-G Antigens/*genetics
MH  - Humans
MH  - INDEL Mutation/*genetics
MH  - Kaplan-Meier Estimate
MH  - Kidney Failure, Chronic/complications/*genetics
MH  - Linkage Disequilibrium/genetics
MH  - Male
MH  - Promoter Regions, Genetic/*genetics
MH  - Solubility
OTO - NOTNLM
OT  - HLA-G 14-bp insertion/deletion
OT  - HLA-G 5' URR
OT  - acute allograft rejection
OT  - cytomegalovirus infection
OT  - end-stage renal disease
OT  - soluble HLA-G
EDAT- 2013/10/18 06:00
MHDA- 2014/06/21 06:00
CRDT- 2013/10/18 06:00
PHST- 2012/12/27 00:00 [received]
PHST- 2013/08/27 00:00 [revised]
PHST- 2013/09/06 00:00 [accepted]
PHST- 2013/10/18 06:00 [entrez]
PHST- 2013/10/18 06:00 [pubmed]
PHST- 2014/06/21 06:00 [medline]
AID - 10.1111/tan.12210 [doi]
PST - ppublish
SO  - Tissue Antigens. 2013 Nov;82(5):317-26. doi: 10.1111/tan.12210.